Trial Profile
Pharmacokinetics, safety and efficacy of a new gadolinium-based contrast agent, gadopiclenol, in pediatric patients from 2 to 17 years of age undergoing contrast-enhanced MRI
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2022
Price :
$35
*
At a glance
- Drugs Gadopiclenol (Primary)
- Indications CNS disorders
- Focus Pharmacokinetics
- Sponsors Guerbet
- 25 Jul 2022 Results evaluating the pharmacokinetic (PK) profile, safety, and efficacy of gadopiclenol in children aged 2 to 17 years, published in the Investigative Radiology
- 31 Oct 2020 This trial has been completed in Poland according to European Clinical Trials Database record.
- 25 Aug 2020 Status changed from recruiting to completed.